Identifying genetic variants linked to hypertension in breast cancer patients treated with bevacizumab
Official title: Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Run by National Cancer Institute (NCI) · NCT02610413 · Data updated 2026-11-12
This study is trying to find out if certain genetic traits make breast cancer patients more likely to develop high blood pressure while being treated with a drug called bevacizumab.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 354 (estimated) |
| Sponsor | National Cancer Institute (NCI) NIH |
| Drugs / interventions | bevacizumab |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | March 25, 2014 |
| Main results expected | January 1, 2100 |
| Study ends | January 1, 2100 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT02610413 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include European American patients who have either developed severe hypertension during bevacizumab treatment or those who did not experience hypertension after completing the treatment.
✕Probably not a fit
Patients who are not of European American descent or those who did not receive bevacizumab for breast cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research focuses on using whole exome sequencing to analyze germline DNA samples from patients with breast cancer who have experienced hypertension while receiving bevacizumab. The primary goal is to identify rare genetic variants that may contribute to the risk of hypertension in these patients. By studying previously collected DNA samples, researchers aim to uncover biomarkers that could help in understanding the genetic factors associated with hypertension in this specific patient population.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of hypertension in breast cancer patients undergoing treatment with bevacizumab.
How similar studies have gone: While this approach is innovative, it builds on existing knowledge of genetic factors in hypertension, and similar studies have shown promise in identifying genetic variants related to other conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * European American patients with deoxyribonucleic acid (DNA) available and designated case or control * Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab * Patients who did not develop hypertension following a full course of treatment with bevacizumab
Where it's running
-
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer
This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.
-
HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma
This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.
-
Bevacizumab for severe HHT-related nosebleeds
This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.
-
Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer
This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.
-
Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer
This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.
-
Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer
This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.